查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1456879

MRI 人工智慧 (AI) 市场 – 2024 年至 2029 年预测

Artificial Intelligence (AI) in MRI Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

MRI 领域的人工智慧 (AI) 市场预计将以 37.14% 的复合年增长率成长，从 2022 年的 2.37 亿美元增至 2029 年的 21.6 亿美元。

MRI 人工智慧 (AI) 市场的推动因素包括跨行业合作和伙伴关係的增加、政府支持使用基于人工智慧的技术的倡议、医疗领域的人工智慧 (AI) 工具以及私营公司的兴趣人工智慧新兴企业受到多种因素的推动，其中包括资金的增加。近年来，人们对具有机器学习功能的医疗设备的兴趣增加。 FDA 审查并核准了越来越多的在过去使用 ML 合法销售的设备（透过 510(k) 许可、批准 De Novo 请求并核准PMA），并且这种趋势仍在继续。我们预测这种情况将继续下去将来。例如，根据 OECD资料，2022 年芬兰磁振造影(MRI) 设备的普及为每百万人 33.16 台，挪威每百万人拥有 31.33 台。随着MRI的普及，人工智慧在MRI中的引入显着增加。

市场驱动力

  • 对医学影像服务的需求不断增长正在刺激市场成长。

医疗保健专业人员可以使用人工智慧演算法提供更准确、更有效的诊断服务、减少等待时间并改善患者治疗结果。美国国立卫生研究院 (NIH) 报告称，对医学影像服务的需求正在增加，其中 MRI 是最受欢迎的模式之一。 2023 年 6 月，美国食品药物管理局(FDA) 授予最新的人工智慧专利 Ezra Flash 510(k) 授权。 Ezra 是一家医疗人工智慧公司，利用全身 MRI 影像彻底改变早期癌症诊断。人工智慧和磁振造影（MRI）领域的智慧财产权不断扩大预计将为行业参与企业提供利润丰厚的机会，并加强人工智慧在 MRI 市场成长中的作用。

  • 阿兹海默症的盛行率日益上升，为人工智慧在 MRI 应用中的应用创造了新的成长前景。

在 PLOS ONE 最近发表的一项研究中，马萨诸塞州总医院 (MGH) 的研究人员分析了脑部磁振造影(MRI)资料，并使用深度学习人工智慧 (AI) 来识别阿兹海默症。我们描述瞭如何建立和测试该模型。阿兹海默症协会使用美国人口普查局的 2023 年人口预测以及芝加哥健康与老龄化计划(CHAP) 的最新信息，该计画是一项以人口为基础的研究，针对影响老年人的慢性健康状况进行研究。研究确定了65 岁以上的大致人数患有老年痴呆症失智症的人。此外，2023 年 3 月，研究人员创建了一个机器学习模型来早期检测阿兹海默症。该模型可以透过智慧型手机访问，能够以 70-75% 的准确率区分阿兹海默症和健康个体。透过专注于语音模式而不是内容，该技术可以提供重要的早期指标，以便更快地开始治疗并延缓疾病的发作。

  • 主要国家癌症患者增加推动市场成长

MRI 主要用于诊断影响软组织的疾病，例如肿瘤，包括癌症。根据美国卫生统计中心的数据，美国新登记的癌症患者人数为1,958,310人，2023年癌症死亡人数预计为6,098,820人。美国癌症患者的增加增加了对人工智慧的需求，这反过来又预计会增加对人工智慧等先进技术的需求，以帮助在预测期内提供更精确的治疗。

预计北美将出现显着成长。

由于美国等主要区域经济体医疗保健基础设施的增加以及先进医疗技术的不断采用提供了新的市场成长机会，预计北美地区将占据重要的市场占有率。此外，美国人均医疗保健支出的增加也促进了支出的增加。例如，美国医疗保险和医疗补助服务中心 (CMS gov.) 2021 年的人均医疗保健支出为 12,914 美元。

人工智慧越来越普遍地应用于磁振造影(MRI) 扫描的各个方面，以提高影像品质、优化流程并协助诊断医疗状况。人工智慧可以透过减少杂讯和伪影来提高 MRI 影像的质量，从而可以从低解析度扫描创建高解析度影像，从而提高诊断准确性。

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章 MRI 中的人工智慧 (AI) 市场：按解决方案

  • 介绍
  • 软体
    • 市场趋势和机会
    • 成长前景
  • 服务
    • 市场趋势和机会
    • 成长前景

第六章 MRI 中的人工智慧 (AI) 市场：按最终用户划分

  • 介绍
  • 医院
    • 市场趋势和机会
    • 成长前景
  • 诊所
    • 市场趋势和机会
    • 成长前景
  • 诊断中心
    • 市场趋势和机会
    • 成长前景

第七章 MRI 领域的人工智慧 (AI) 市场：按地区

  • 介绍
  • 北美洲
    • 按解决方案
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按解决方案
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按解决方案
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 按解决方案
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按解决方案
    • 按最终用户
    • 按国家/地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章 公司简介

  • Siemens Healthineers AG
  • GE HealthCare
  • IBM
  • Philips Healthcare
  • NVIDIA Corporation
  • Oxipit.ai
  • Quibim
简介目录
Product Code: KSI061614835

The Artificial intelligence (AI) in MRI market is projected to grow at a CAGR of 37.14% to reach US$2.160 billion in 2029 from US$0.237 billion in 2022.

Artificial intelligence in the MRI market is being driven by several factors, including an increase in cross-industry collaborations and partnerships, government initiatives to support the use of AI-based technologies, artificial intelligence (AI) tools in the medical sector, and increased funding for AI-based start-ups by private players. In recent years, there has been a rise in interest in medical devices with ML capabilities. The FDA has examined and approved an increasing number of devices that have been lawfully sold (through 510(k) clearance, granted De Novo request, or approved PMA) with ML in the past, and it anticipates that this trend will continue. For instance, as per OECD data, magnetic resonance imaging (MRI) Units in 2022 were 33.16 per million inhabitants in Finland, and for Norway, the value was 31.33. With the increasing use of MRIs, the inculcation of AI in them is significantly increasing.

Market Drivers

  • Rising demand for medical imaging services has stimulated the market growth.

Healthcare practitioners may use AI algorithms to deliver more precise and effective diagnostic services, cutting down on wait times and increasing patient outcomes. The US National Institutes of Health (NIH) reports that there is a rising demand for medical imaging services, with MRI being one of the most popular modalities. The U.S. Food and Drug Administration (FDA), in June 2023, gave Ezra Flash, its newest patented artificial intelligence, 510(k) certification. Ezra is a healthcare AI firm that is revolutionizing early cancer diagnosis using whole-body MRI imaging. The increasing expansion of intellectual property in the domain of artificial intelligence and magnetic resonance imaging (MRI) is expected to offer lucrative opportunities to the industry players and bolster artificial intelligence in the MRI market growth.

  • Growing prevalence of Alzheimer has provided new growth prospects for AI in MRI application.

In a recent study that was published in PLOS ONE, researchers from Massachusetts General Hospital (MGH) described how they created and tested a deep-learning artificial intelligence (AI) model to analyze data from brain magnetic resonance images (MRIs) and identify Alzheimer's disease. The Alzheimer's Association study using the most recent information from the U.S. Census Bureau's population projections for 2023 and the Chicago Health and Ageing Project (CHAP), a population-based study of chronic health conditions affecting older people, has determined the approximate number of people aged 65 and older who have Alzheimer's dementia. Further, in March 2023, researchers created a machine-learning model to detect Alzheimer's disease early. This model, which may be accessed via smartphones, can discriminate between people with Alzheimer's disease and healthy people with an accuracy of 70-75%. The technology might provide important early indicators by concentrating on speech patterns rather than content, thus starting therapy sooner and delaying illness development.

  • Growth in cancer cases in major economies has bolstered the market growth

MRI is majorly used to diagnose conditions that affect soft tissues such as tumors including cancer. According to the National Center for Health Statistics, the new cancer cases registered in the United States were 1,958,310, and cancer deaths were estimated to be 6,09,820 in the year 2023. Such increasing cases of cancer in the United States are increasing the demand for AI which in turn is anticipated to increase the need for advanced technologies such as artificial intelligence that can help in better precision in the projected period.

North America is anticipated to show significant growth.

The North American region is expected to account for considerable market share fueled by the increasing medical infrastructure in major regional economies such as United States coupled with growing advanced medical technologies adoption which has provided new market growth opportunities. Moreover, the increased per capita healthcare spending by the people of the United States can also be one of the reasons for increased spending. For instance, the U.S. Centers for Medicare & Medicaid Services (CMS gov.) per capita healthcare spending was US$ 12,914 per person in 2021.

Artificial Intelligence is being more commonly applied in different facets of MRI (Magnetic Resonance Imaging) scans, aiming to enhance image quality, optimize processes, and assist in diagnosing medical conditions. AI can improve the quality of MRI images by diminishing noise and artifacts, allowing for the creation of higher-resolution images from lower-resolution scans, thereby enhancing the precision of diagnoses.

Key Developments

  • In November 2023: GE Healthcare introduced "SIGNA Champion" which is 1.5T wide bore MRI system equipped with advanced AI and innovative features that enhances the standard MRI procedures and develops precise scans.
  • In June 2023, Sonic DL (GE HealthCare), a deep learning program that may alter scan time expectations and perhaps increase the number of patients who are eligible for cardiac magnetic resonance imaging (MRI), received 510(k) approval from the Food and Drug Administration (FDA).
  • In July 2022, the FDA approved Philips SmartSpeed AI-based software, allowing it to provide industry-first high-speed, high-resolution MR imaging.

Segmentation:

By Solution

  • Software
  • Services

By End-User

  • Hospitals
  • Clinics
  • Diagnostic Centers

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Singapore
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits for the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. ARTIFICIAL INTELLIGENCE (AI) IN MRI MARKET BY SOLUTION

  • 5.1. Introduction
  • 5.2. Software
    • 5.2.1. Market Trends and Opportunities
    • 5.2.2. Growth Prospects
  • 5.3. Services
    • 5.3.1. Market Trends and Opportunities
    • 5.3.2. Growth Prospects

6. ARTIFICIAL INTELLIGENCE (AI) IN MRI MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Hospitals
    • 6.2.1. Market Trends and Opportunities
    • 6.2.2. Growth Prospects
  • 6.3. Clinics
    • 6.3.1. Market Trends and Opportunities
    • 6.3.2. Growth Prospects
  • 6.4. Diagnostic Centers
    • 6.4.1. Market Trends and Opportunities
    • 6.4.2. Growth Prospects

7. ARTIFICIAL INTELLIGENCE (AI) IN MRI MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Solution
    • 7.2.2. By End-User
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Trends and Opportunities
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Trends and Opportunities
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Trends and Opportunities
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Solution
    • 7.3.2. By End-User
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Trends and Opportunities
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Trends and Opportunities
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Trends and Opportunities
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Solution
    • 7.4.2. By End-User
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
        • 7.4.3.1.1. Market Trends and Opportunities
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Trends and Opportunities
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. France
        • 7.4.3.3.1. Market Trends and Opportunities
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Italy
        • 7.4.3.4.1. Market Trends and Opportunities
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Spain
        • 7.4.3.5.1. Market Trends and Opportunities
        • 7.4.3.5.2. Growth Prospects
      • 7.4.3.6. Others
        • 7.4.3.6.1. Market Trends and Opportunities
        • 7.4.3.6.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Solution
    • 7.5.2. By End-User
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Trends and Opportunities
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Trends and Opportunities
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Trends and Opportunities
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Solution
    • 7.6.2. By End-User
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Trends and Opportunities
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. Japan
        • 7.6.3.2.1. Market Trends and Opportunities
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Trends and Opportunities
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. South Korea
        • 7.6.3.4.1. Market Trends and Opportunities
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Australia
        • 7.6.3.5.1. Market Trends and Opportunities
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Singapore
        • 7.6.3.6.1. Market Trends and Opportunities
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Indonesia
        • 7.6.3.7.1. Market Trends and Opportunities
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Trends and Opportunities
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Siemens Healthineers AG
  • 9.2. GE HealthCare
  • 9.3. IBM
  • 9.4. Philips Healthcare
  • 9.5. NVIDIA Corporation
  • 9.6. Oxipit.ai
  • 9.7. Quibim